Search results for: 'market state deaf and alliance of 221b'

Global coverage | Deal financials | Contract documents | Deal trends | Leading M&A dealmakers | Comprehensive deal directory 2021 to 2026

Genomics Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2018 to 2025

Analyze co-development deals in pharma and biotech from 2016 to 2026. Includes financials, deal terms, and access to actual contracts where available.

Companion Diagnostics Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2010 to 2025

Provides comprehensive understanding and unprecedented access to the animal health agreements entered into by the world's leading biopharma companies.

Precision Medicine in Oncology Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2025

Asset Purchase Deals in Pharmaceuticals and Biotechnology | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2019 to 2026

Essential Benchmark Data for Dealmakers  | Global coverage | Updated to 2026 | 11+ years of royalty rates | Deal financials | Contract documents | Royalty rate trends

Antibody Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2019 to 2025

The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report offers in-depth insights and exclusive access to clinical-stage partnering agreements signed by the world’s leading biopharma companies, providing a detailed analysis of deal structures, financial terms and strategic collaborations.